CHIGAGO — Perioperative chemotherapy improved OS in patients with locally advanced esophageal adenocarcinoma compared with chemoradiation prior to surgery, results form a randomized phase 3 trial presented at ASCO Annual Meeting showed.
Study participants who received the FLOT protocol (fluorouracil, leucovorin, oxaliplatin and docetaxel) before and after surgery had a median OS almost 2.5 years longer than those treated with the CROSS regimen (41.4Gy plus carboplatin and paclitaxel), both considered standard of care for the patient population.
“This was our hypothesis,” Jens